PRELID3B

Across TCGA pan-cancer cohorts, PRELID3B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRELID3B data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRELID3B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRELID3B expression acts as an unfavorable survival marker.

LUAD, BLCA, and UCEC are the cancer types where PRELID3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	15	view →
BLCA	DFS	Median	All	0.178	0.616	.006	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRELID3B–LUAD (DFS)

Open the LUAD breakdown →